CRISPR Therapeutics (CRSP) Stock Price, News & Analysis

Company Overview

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals. In addition to hematology, CRISPR Therapeutics is advancing oncology candidates such as CTX110, CTX112 and CTX120, which use engineered immune cells to target various blood cancers. The company also maintains partnerships with organizations including ViaCyte for potential treatments in type 1 diabetes, further diversifying its pipeline across therapeutic areas.

Founded in 2013 and headquartered in Zug, Switzerland, CRISPR Therapeutics maintains a significant presence in the United States, with research and development facilities in Cambridge, Massachusetts. The company’s global footprint supports clinical trials across North America and Europe, reflecting its commitment to addressing unmet medical needs in key healthcare markets worldwide.

Under the leadership of Chief Executive Officer Samarth Kulkarni, CRISPR Therapeutics continues to expand its manufacturing capabilities and prepare for potential regulatory filings. Co-founder Emmanuelle Charpentier, a pioneer in CRISPR science, serves on the board, guiding the company’s strategic direction as it advances a novel class of genetic medicines toward commercialization.

Key Stats

• Today's Range: $69.80 to $73.09
• 50-Day Range: $51.81 to $76.78
• 52-Week Range: $30.04 to $78.48
• Volume: 2.36 million shs
• Average Volume: 2.91 million shs
• Market Capitalization: $6.53 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $71.71
• Consensus Rating: Hold

CRISPR Therapeutics Stock Analysis - MarketRank™

CRISPR Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 796th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

CRISPR Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 10 buy ratings, 7 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for CRISPR Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

CRISPR Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.16) to ($4.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CRISPR Therapeutics is -13.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CRISPR Therapeutics is -13.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CRISPR Therapeutics has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.18% of the outstanding shares of CRISPR Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

CRISPR Therapeutics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in CRISPR Therapeutics has recently increased by 7.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CRISPR Therapeutics does not currently pay a dividend.

Dividend Growth

CRISPR Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

26.18% of the outstanding shares of CRISPR Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

CRISPR Therapeutics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in CRISPR Therapeutics has recently increased by 7.88%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.44

News Sentiment

CRISPR Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for CRISPR Therapeutics this week, compared to 12 articles on an average week.

Search Interest

79 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.

MarketBeat Follows

40 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 54% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, CRISPR Therapeutics insiders have bought 14,440.65% more of their company's stock than they have sold. Specifically, they have bought $51,499,918.00 in company stock and sold $354,179.00 in company stock.

Percentage Held by Insiders

Only 4.30% of the stock of CRISPR Therapeutics is held by insiders.

Percentage Held by Institutions

69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRSP Stock Analysis - Frequently Asked Questions

How have CRSP shares performed this year?

CRISPR Therapeutics' stock was trading at $39.36 at the start of the year. Since then, CRSP stock has increased by 82.5% and is now trading at $71.82.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings results on Monday, August, 4th. The company reported ($1.29) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.18. The business's revenue was up 72.5% compared to the same quarter last year.

When did CRISPR Therapeutics IPO?

CRISPR Therapeutics (CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are CRISPR Therapeutics' major shareholders?

Top institutional investors of CRISPR Therapeutics include Congress Asset Management Co. (0.07%), Green Alpha Advisors LLC (0.06%), Voya Investment Management LLC (0.03%) and Ipswich Investment Management Co. Inc. (0.03%). Insiders that own company stock include Simeon George, Samarth Kulkarni, James R Kasinger, Julianne Bruno, John Greene, Raju Prasad and Naimish Patel.
View institutional ownership trends.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 10/16/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRSP
• CIK: 1674416
• Web: www.crisprtx.com
• Phone: (141) 561-3277
• Fax: N/A
• Employees: 460
• Year Founded: 2013

Price Target and Rating

• Average Price Target for CRISPR Therapeutics: $71.71
• High Price Target: $120.00
• Low Price Target: $32.00
• Potential Upside/Downside: -0.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.42
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$366.25 million
• Net Margins: -1,229.43%
• Pretax Margin: -1,218.98%
• Return on Equity: -20.05%
• Return on Assets: -17.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.61
• Quick Ratio: 16.61

Sales & Book Value

• Annual Sales: $35 million
• Price / Sales: 186.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.64 per share
• Price / Book: 3.17

Miscellaneous

• Outstanding Shares: 90,950,000
• Free Float: 87,039,000
• Market Cap: $6.53 billion
• Optionable: Optionable
• Beta: 1.84